Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Svarstad, E.
Right arrow Articles by Ofstad, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Svarstad, E.
Right arrow Articles by Ofstad, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (1994) 9: 1462-1467
© 1994 European Renal Association-European Dialysis and Transplant Association

research-article

Renal effects of maintenance low-dose cyclosporin A treatment in psoriasis

E. Svarstad1,, S. Helland2, T. Morken2, L. Bostad3, A. Myking3, B. M. Iversen1 and J. Ofstad1

1Renal Research Group, Medical Department University of Bergen Bergen, Norway 2Dept. of Dermatology, University of Bergen Bergen, Norway 3The Gade Institute, Dept. of Pathology, University of Bergen Bergen, Norway

Correspondence and offprint requests to: Correspondence and offprint requests to: E. Svarstad, MD, Medical Dept. A, Haukeland Hospital, 5021 Bergen, Norway

The renal effects of low-dose cyclosporin A (CsA) treatment in severe psoriasis was investigated in 10 patients treated with a mean CsA dose of 3.23 (range 1.94–4.10) mg/kg/day for 12 months. The psoriasis area and severity index was reduced by 63–76%. Ambulatory GFR (iothalamate-125I) ERPF (hippuran-131), RVR and MAP were examined at 3-months intervals. A control renal biopsy was performed shortly before treatment start and a second biopsy was taken after 12 months of therapy. GFR was slightly but significantly reduced after 6 and 9 months; after 12 months the decrease was not significant (121.0±7.6 versus 115.2±7.8 ml/min/l.73M P>0.10). After 12 months serum creatinine increased from 82±4 to 94±7 µmol/litre (P<0.05 while an insignificant increase of ERPF was seen and FF decreased from 0.29±0.01 to 0.26±0.01 (P<0.05). MAP remained unchanged. GFR and serum creatinine correlated significantly within each 3-month interval. A slight de novo interstitial fibrosis was seen in the second biopsy in 4 of 10 patients receiving a mean CsA dose of 3.2–4.1 mg/kg/day. In three of these patients a concomitant rise in serum creatinine was seen.

In conclusion, low-dose CsA was associated with reversible fall in GFR and potentially progressive structural changes not always accompanied by corresponding functional alterations. One should consider reducing the daily dose of CsA to 3.0 mg/kg body- weight or less in CsA therapy up to 1 year.

Keywords: ambulatory position; cyclosporin A; GFR; psoriasis; renal biopsy; renal haemodynamics


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.